Keywords: Sanofi-Aventis, Vivalis, MAb, Infectious diseases, Sanofi Pasteur, Zealand Pharma, Lantus, Lixisenatide, Diabetes

Sanofi-Aventis in licensing deal with Vivalis for MAb targeting infectious diseases and extends accord with Zealand for diabetes product

Article | 08 June 2010

Print This

In what was another busy licensing day for French drug major Sanofi-Aventis, which since 2008 has already spent around $9 billion on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in